HRP20150162T1 - Antikin antitijela koja se vežu na višestruke cc kemokine - Google Patents
Antikin antitijela koja se vežu na višestruke cc kemokine Download PDFInfo
- Publication number
- HRP20150162T1 HRP20150162T1 HRP20150162TT HRP20150162T HRP20150162T1 HR P20150162 T1 HRP20150162 T1 HR P20150162T1 HR P20150162T T HRP20150162T T HR P20150162TT HR P20150162 T HRP20150162 T HR P20150162T HR P20150162 T1 HRP20150162 T1 HR P20150162T1
- Authority
- HR
- Croatia
- Prior art keywords
- mip
- antigen
- binding fragment
- monoclonal antibody
- ccl4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
| EP20100812667 EP2470671B1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150162T1 true HRP20150162T1 (hr) | 2015-05-08 |
Family
ID=43628404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150162TT HRP20150162T1 (hr) | 2009-08-28 | 2010-08-27 | Antikin antitijela koja se vežu na višestruke cc kemokine |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (enExample) |
| EP (1) | EP2470671B1 (enExample) |
| JP (2) | JP6109571B2 (enExample) |
| KR (1) | KR101778813B1 (enExample) |
| CN (1) | CN102782148B (enExample) |
| AU (1) | AU2010286516B2 (enExample) |
| BR (1) | BR112012004387A2 (enExample) |
| CA (1) | CA2771781C (enExample) |
| DK (1) | DK2470671T3 (enExample) |
| ES (1) | ES2531561T3 (enExample) |
| HR (1) | HRP20150162T1 (enExample) |
| IN (1) | IN2012DN01769A (enExample) |
| MX (1) | MX2012002427A (enExample) |
| PL (1) | PL2470671T3 (enExample) |
| PT (1) | PT2470671E (enExample) |
| SI (1) | SI2470671T1 (enExample) |
| SM (1) | SMT201500011B (enExample) |
| WO (1) | WO2011025962A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011025962A1 (en) * | 2009-08-28 | 2011-03-03 | Dan Allison | Antikine antibodies that bind to multiple cc chemokines |
| DK2717941T3 (da) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
| CA2912443A1 (en) * | 2013-05-23 | 2014-11-27 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| EP3611191A1 (en) * | 2013-12-09 | 2020-02-19 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
| JP6825909B2 (ja) | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | シグレック−８関連疾患を処置するための方法および組成物 |
| DK3114139T3 (da) * | 2014-03-04 | 2022-09-12 | Chemomab Ltd | Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI566780B (zh) * | 2014-10-24 | 2017-01-21 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途 |
| EP3808775B1 (en) * | 2014-12-09 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | CANCER TREATMENT COMBINATIONS |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7122002B2 (ja) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| BR112019020909A2 (pt) * | 2017-04-05 | 2020-05-12 | Korea Research Institute Of Bioscience And Biotechnology | Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma |
| BR112019022912A2 (pt) | 2017-05-05 | 2020-05-26 | Allakos Inc. | Métodos e composições para tratar doenças oculares alérgicas |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| WO2019075472A1 (en) * | 2017-10-13 | 2019-04-18 | A&G Pharmaceutical, Inc. | MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
| JP2021509120A (ja) * | 2017-12-28 | 2021-03-18 | アスチュート メディカル，インコーポレイテッド | Ｃｃｌ１４に関する抗体およびアッセイ |
| WO2019165397A1 (en) * | 2018-02-26 | 2019-08-29 | Cornell University | Quantitative biomarkers of ehv-1 susceptibility and protection |
| WO2019217705A1 (en) * | 2018-05-11 | 2019-11-14 | Proplex Technologies, LLC | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| CN114341178B (zh) * | 2019-07-02 | 2024-05-07 | 机敏医药股份有限公司 | Ccl14的抗体和检测 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| WO2022011110A2 (en) * | 2020-07-08 | 2022-01-13 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| CA3198647A1 (en) * | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| HRP20050986A2 (en) | 2002-08-19 | 2006-11-30 | Abgenix | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| CA2507080C (en) * | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| EP1828234B1 (en) | 2004-12-21 | 2009-03-25 | Laboratoires Serono S.A. | Cc-chemokine antagonists |
| MX2010001307A (es) | 2007-08-02 | 2010-07-30 | Novimmune Sa | Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. |
| WO2011025962A1 (en) * | 2009-08-28 | 2011-03-03 | Dan Allison | Antikine antibodies that bind to multiple cc chemokines |
-
2010
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150166647A1 (en) | 2015-06-18 |
| US20130108640A1 (en) | 2013-05-02 |
| CA2771781C (en) | 2019-01-15 |
| KR20120091013A (ko) | 2012-08-17 |
| US9005617B2 (en) | 2015-04-14 |
| SMT201500011B (it) | 2015-03-05 |
| WO2011025962A1 (en) | 2011-03-03 |
| US8313747B2 (en) | 2012-11-20 |
| AU2010286516A1 (en) | 2012-03-08 |
| AU2010286516B2 (en) | 2016-10-06 |
| JP6109571B2 (ja) | 2017-04-05 |
| MX2012002427A (es) | 2012-08-03 |
| CN102782148A (zh) | 2012-11-14 |
| PT2470671E (pt) | 2015-02-05 |
| PL2470671T3 (pl) | 2015-05-29 |
| US20110059107A1 (en) | 2011-03-10 |
| RU2012111820A (ru) | 2013-10-10 |
| EP2470671B1 (en) | 2014-12-24 |
| EP2470671A4 (en) | 2013-04-03 |
| CN102782148B (zh) | 2016-04-20 |
| IN2012DN01769A (enExample) | 2015-06-05 |
| CA2771781A1 (en) | 2011-03-03 |
| JP2013503192A (ja) | 2013-01-31 |
| SI2470671T1 (sl) | 2015-04-30 |
| BR112012004387A2 (pt) | 2015-09-08 |
| ES2531561T3 (es) | 2015-03-17 |
| AU2010286516A2 (en) | 2012-06-14 |
| EP2470671A1 (en) | 2012-07-04 |
| DK2470671T3 (en) | 2015-02-09 |
| JP2016135783A (ja) | 2016-07-28 |
| KR101778813B1 (ko) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503192A5 (enExample) | ||
| Greenfield | Antibodies | |
| Bonvin et al. | De novo isolation of antibodies with pH-dependent binding properties | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| HRP20250482T1 (hr) | Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe | |
| EP4036116A1 (en) | Anti-vhh domain antibodies and use thereof | |
| AU2013310924B2 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
| ES2531561T3 (es) | Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| EP2759549A3 (en) | IL-31 monoclonal antibodies and methods of use | |
| IL309975A (en) | Antibodies against C5 and their uses | |
| HRP20160461T1 (hr) | Solubilna humana st-2 antitijela i eseji | |
| RU2010129558A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| JP2020535799A5 (enExample) | ||
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| JP2016135783A5 (enExample) | ||
| JP2013545438A5 (enExample) | ||
| RU2012151478A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2021500916A5 (enExample) | ||
| RU2010132647A (ru) | Анти-mif антитела | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| SI2768859T1 (en) | Antagonists of il17c for the treatment of inflammatory disorders |